Everest Organics Downgraded to Strong Sell Amid Mixed Valuation and Weak Financial Trends

Quality Assessment: Weakening Fundamentals and Profitability

Everest Organics’ quality grade remains a significant concern, underpinning the downgrade. The company has exhibited a weak long-term fundamental strength, with a negative compound annual growth rate (CAGR) of -7.30% in operating profits over the past five years. This decline signals persistent challenges in scaling operational efficiency and profitability.

Return on Equity (ROE) further highlights the company’s struggles, with an average ROE of just 2.02%, indicating low profitability generated per unit of shareholders’ funds. The latest ROE stands at 7.37%, which, while improved, remains modest compared to industry standards. Return on Capital Employed (ROCE) is somewhat better at 10.68%, but still insufficient to offset concerns about operational performance.

Quarterly financials for Q4 FY25-26 reveal flat performance, with profit after tax (PAT) for the latest six months at ₹2.99 crores, reflecting a sharp decline of -26.17%. Operating profit to interest coverage ratio has dropped to a low 2.43 times, signalling limited ability to service debt comfortably. Additionally, the debtors turnover ratio at 1.63 times is among the lowest, pointing to inefficiencies in receivables management.

Valuation: From Very Attractive to Attractive but Still Discounted

Valuation metrics have seen a subtle shift, with Everest Organics’ valuation grade moving from very attractive to attractive. The company’s price-to-earnings (PE) ratio stands at 49.76, which is high in absolute terms but comparatively reasonable within its peer group, many of whom are classified as very expensive or risky. For instance, Bliss GVS Pharma and Kwality Pharma trade at PE ratios of 41.53 and 38.91 respectively but are rated very expensive due to other valuation factors.

Enterprise value to EBITDA (EV/EBITDA) is 16.45, which is lower than several peers such as Ind-Swift Laboratories at 48.53 and Shukra Pharma at 52.46, suggesting Everest Organics is trading at a relative discount. The PEG ratio of 0.09 is particularly notable, indicating that the stock’s price growth is low relative to earnings growth potential, a factor that typically appeals to value investors.

Enterprise value to capital employed (EV/CE) is 2.61, reinforcing the notion of an attractive valuation relative to the capital base. Despite this, the stock price remains subdued, currently at ₹284.65, well below its 52-week high of ₹536.40, reflecting market scepticism about the company’s growth prospects.

Financial Trend: Flat to Negative Performance Amid Debt Concerns

Financial trends for Everest Organics have been largely disappointing, contributing to the downgrade. The company’s operating profit growth has been negative over the last five years, and recent quarterly results confirm a flat trajectory. The PAT decline of -26.17% over the last six months is a stark indicator of operational challenges.

Debt servicing capacity is under pressure, with a Debt to EBITDA ratio of 2.52 times, which is relatively high for a micro-cap pharmaceutical firm. This elevated leverage raises concerns about financial risk, especially given the low interest coverage ratio of 2.43 times. Such metrics suggest the company may face difficulties in meeting its debt obligations if profitability does not improve.

Comparatively, Everest Organics has underperformed the broader market indices. Over the past year, the stock has declined by -16.28%, while the Sensex and BSE500 indices have fallen by -6.31% and -1.10% respectively. This underperformance reflects investor caution amid the company’s weak fundamentals and uncertain growth outlook.

Technicals: Short-Term Gains Amid Long-Term Weakness

Technically, Everest Organics has shown some short-term strength, with a day change of +4.00% and a one-week return of 14.02%, significantly outperforming the Sensex’s 2.23% gain over the same period. The one-month return is also robust at 19.20%, compared to the Sensex’s 5.30%.

However, these short-term gains contrast sharply with the longer-term picture. The year-to-date (YTD) return is -43.72%, and the five-year return is negative at -18.59%, both lagging the Sensex’s positive returns over these periods. The stock’s 10-year return of 802.22% is impressive but may reflect past performance rather than current fundamentals.

Price action remains volatile, with the current price of ₹284.65 well below the 52-week high of ₹536.40 and above the 52-week low of ₹197.00. This wide trading range indicates uncertainty and lack of sustained investor confidence.

Peer Comparison and Market Positioning

Within the Pharmaceuticals & Biotechnology sector, Everest Organics is classified as a micro-cap company with a Mojo Score of 28.0 and a Mojo Grade of Strong Sell, downgraded from Sell. This rating reflects the company’s relative position in the market and its financial health compared to peers.

Peers such as Bliss GVS Pharma, Kwality Pharma, and Venus Remedies are rated very expensive or expensive, with higher PE and EV/EBITDA ratios, but they also demonstrate stronger financial trends and profitability metrics. Everest Organics’ attractive valuation metrics, including a low PEG ratio of 0.09, suggest potential value, but this is overshadowed by weak fundamentals and financial risks.

Majority shareholding remains with promoters, which may provide some stability, but the company’s operational and financial challenges require significant improvement to regain investor confidence.

Conclusion: Downgrade Reflects Caution Amid Mixed Signals

The downgrade of Everest Organics Ltd to Strong Sell is driven by a combination of factors. While valuation metrics have improved slightly, moving from very attractive to attractive, the company’s weak financial trends, poor profitability, and high leverage present significant risks. Short-term technical gains have not translated into sustained performance, and the stock continues to underperform the broader market over longer horizons.

Investors should approach Everest Organics with caution, considering the company’s flat recent financial results, low operating profit growth, and debt servicing challenges. The downgrade signals a need for substantial operational turnaround before the stock can be reconsidered as a viable investment option within the Pharmaceuticals & Biotechnology sector.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →